Cogent Biosciences (COGT) EBITDA: 2017-2020
Historic EBITDA for Cogent Biosciences (COGT) over the last 4 years, with Dec 2020 value amounting to -$74.8 million.
- Cogent Biosciences' EBITDA fell 593.60% to -$11.3 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$74.8 million, marking a year-over-year decrease of 135.09%. This contributed to the annual value of -$74.8 million for FY2020, which is 135.09% down from last year.
- According to the latest figures from FY2020, Cogent Biosciences' EBITDA is -$74.8 million, which was down 135.09% from -$31.8 million recorded in FY2019.
- In the past 5 years, Cogent Biosciences' EBITDA ranged from a high of -$25.5 million in FY2017 and a low of -$74.8 million during FY2020.
- Its 3-year average for EBITDA is -$47.1 million, with a median of -$34.5 million in 2018.
- Its EBITDA has fluctuated over the past 5 years, first grew by 7.84% in 2019, then slumped by 135.09% in 2020.
- Yearly analysis of 4 years shows Cogent Biosciences' EBITDA stood at -$25.5 million in 2017, then plummeted by 35.49% to -$34.5 million in 2018, then grew by 7.84% to -$31.8 million in 2019, then slumped by 135.09% to -$74.8 million in 2020.